Advanced Dual-Nuclei MRI to Differentiate Recurrent Brain Metastases and Radiation Necrosis

What this Trial Is About

Researchers are evaluating advanced magnetic resonance imaging (MRI) techniques, including diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, to distinguish between recurrent brain tumors and radiation-related tissue damage called radiation necrosis (RN). These conditions often look similar on standard MRI scans, making it difficult for doctors to decide the best treatment approach. This study aims to develop new imaging methods to improve diagnosis and predict treatment outcomes in patients with metastatic brain tumors. The study has two parts. In the first, patients scheduled for surgical removal or biopsy of brain tumors undergo advanced DR-CSI and sodium MRI scans lasting about 30 minutes before their standard care. Tissue samples are also collected for analysis. In the second part, patients scheduled for stereotactic radiosurgery (SRS) receive the same advanced MRI scans before treatment and then again at 2 weeks, 3 months, and 6 months after SRS. Clinical MRIs accompany both parts to track changes over time. Participants will undergo multiple imaging sessions and, for some, tissue sampling. The study measures imaging features of recurrent brain metastases and radiation necrosis, correlates imaging with tissue analysis, and monitors early imaging changes to predict clinical outcomes. These assessments occur before surgery or biopsy in the first part and at specified intervals after SRS in the second. The total involvement duration varies depending on the assigned part of the study, with close monitoring throughout.

Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis